Head to Head Contrast: Monogram Orthopaedics (NASDAQ:MGRM) versus RxSight (NASDAQ:RXST)

RxSight (NASDAQ:RXST) and Monogram Orthopaedics (NASDAQ:MGRM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Insider & Institutional Ownership

78.8% of RxSight shares are owned by institutional investors. Comparatively, 0.4% of Monogram Orthopaedics shares are owned by institutional investors. 9.6% of RxSight shares are owned by company insiders. Comparatively, 28.1% of Monogram Orthopaedics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for RxSight and Monogram Orthopaedics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	2	9	1	0	1.92
Monogram Orthopaedics	0	0	1	1	3.50

RxSight presently has a consensus price target of $10.00, indicating a potential upside of 6.61%. Monogram Orthopaedics has a consensus price target of $5.40, indicating a potential downside of 9.24%. Given RxSight’s higher probable upside, equities research analysts clearly believe RxSight is more favorable than Monogram Orthopaedics.

Risk and Volatility

RxSight has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Monogram Orthopaedics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Profitability

This table compares RxSight and Monogram Orthopaedics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RxSight	-21.93%	-11.56%	-10.31%
Monogram Orthopaedics	N/A	-126.82%	-96.87%

Earnings & Valuation

This table compares RxSight and Monogram Orthopaedics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$139.93 million	2.74	-$27.45 million	($0.80)	-11.73
Monogram Orthopaedics	N/A	N/A	-$16.33 million	($0.50)	-11.90

Monogram Orthopaedics has lower revenue, but higher earnings than RxSight. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Summary

RxSight beats Monogram Orthopaedics on 7 of the 13 factors compared between the two stocks.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.